[go: up one dir, main page]

NO20000093L - (+)-Norcisaprid nyttig for 5-HT3 og 5-HT4-medierte forstyrrelser - Google Patents

(+)-Norcisaprid nyttig for 5-HT3 og 5-HT4-medierte forstyrrelser

Info

Publication number
NO20000093L
NO20000093L NO20000093A NO20000093A NO20000093L NO 20000093 L NO20000093 L NO 20000093L NO 20000093 A NO20000093 A NO 20000093A NO 20000093 A NO20000093 A NO 20000093A NO 20000093 L NO20000093 L NO 20000093L
Authority
NO
Norway
Prior art keywords
norcisapride
useful
mediated disorders
intestinal disorders
treating gastro
Prior art date
Application number
NO20000093A
Other languages
English (en)
Other versions
NO20000093D0 (no
NO315183B1 (no
Inventor
Jozef Jan Pieter Heykants
Antonius Adrianus Hendr Megens
Willem Emiel Gusta Meuldermans
Joannes Adrianus Jac Schuurkes
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20000093D0 publication Critical patent/NO20000093D0/no
Publication of NO20000093L publication Critical patent/NO20000093L/no
Publication of NO315183B1 publication Critical patent/NO315183B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Preparing Plates And Mask In Photomechanical Process (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20000093A 1997-07-11 2000-01-07 Anvendelse av (+) -norcisaprid for fremstilling av medikamenter NO315183B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97202161 1997-07-11
EP98200661 1998-03-04
PCT/EP1998/004193 WO1999002496A1 (en) 1997-07-11 1998-07-07 (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders

Publications (3)

Publication Number Publication Date
NO20000093D0 NO20000093D0 (no) 2000-01-07
NO20000093L true NO20000093L (no) 2000-03-10
NO315183B1 NO315183B1 (no) 2003-07-28

Family

ID=26146686

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000093A NO315183B1 (no) 1997-07-11 2000-01-07 Anvendelse av (+) -norcisaprid for fremstilling av medikamenter

Country Status (30)

Country Link
US (2) US20030060485A1 (no)
EP (1) EP1000029B1 (no)
JP (1) JP3529102B2 (no)
KR (1) KR100358374B1 (no)
CN (1) CN1196681C (no)
AT (1) ATE251139T1 (no)
AU (1) AU757077B2 (no)
BG (1) BG64824B1 (no)
BR (1) BR9811676A (no)
CA (1) CA2292480A1 (no)
CO (1) CO4940432A1 (no)
CZ (1) CZ296212B6 (no)
DE (1) DE69818678T2 (no)
DK (1) DK1000029T3 (no)
EA (1) EA002362B1 (no)
EE (1) EE04491B1 (no)
ES (1) ES2209190T3 (no)
HR (1) HRP20000004A2 (no)
HU (1) HUP0003078A3 (no)
ID (1) ID24228A (no)
IL (1) IL133225A (no)
MY (1) MY129130A (no)
NO (1) NO315183B1 (no)
NZ (1) NZ502207A (no)
PL (1) PL190296B1 (no)
PT (1) PT1000029E (no)
SK (1) SK284941B6 (no)
TR (1) TR200000020T2 (no)
TW (1) TW553934B (no)
WO (1) WO1999002496A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147093A (en) 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
KR20060017570A (ko) 1998-06-15 2006-02-23 세프라코 아이엔시. 무호흡증, 대식증, 다른 질환을 치료하기 위한 광학적으로순수한 (+)-노르씨사프라이드의 용도
EP1464333A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
IL140117A0 (en) 1998-06-15 2002-02-10 Sepracor Inc Use of optically pure (-) norcisapride in the treatment of apnea, bulimia and other disorders
EP1468685A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
DK1200090T3 (da) * 1999-08-03 2013-11-25 Icos Corp Farmaceutisk formulering omfattende en beta-carbolin og dens anvendelse til behandling af seksuel dysfunktion
CA2410939C (en) * 2000-06-07 2010-02-16 Aryx Therapeutics Materials and methods for the treatment of gastroesophageal reflux disease
AU2002231627A1 (en) * 2000-11-24 2002-06-03 Janssen Pharmaceutica N.V. Use of a triple combination comprising a 5HT3 antagonist, a 5HT4 agonist and a laxative for promoting intestinal lavage
AU2002356418A1 (en) * 2001-10-08 2003-04-22 Sun Pharmaceutical Industries Limited An antispasmodic agent spaced drug delivery system
JP2003342186A (ja) * 2002-05-24 2003-12-03 Taisho Pharmaceut Co Ltd 鼻炎用内服液剤組成物
DK2194053T3 (da) 2004-01-07 2013-07-01 Armetheon Inc Methoxypiperidinderivater til brug i behandling af gastrointestinale forstyrrelser og forstyrrelser i centralnervesystemet.
US8138204B2 (en) 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US20060247180A1 (en) * 2005-04-29 2006-11-02 Bergey James L Purgative composition and uses thereof
KR101351454B1 (ko) 2005-08-31 2014-01-14 아메데온, 인코포레이티드 위장 및 중추 신경계 장애의 치료에 유용한 입체이성질체 화합물의 합성 방법 및 중간 생성물
KR20100026641A (ko) * 2008-09-01 2010-03-10 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
JP7203083B2 (ja) * 2017-07-19 2023-01-12 イグナイタ インコーポレイテッド エントレクチニブを含む薬学的組成物
US20210290593A1 (en) * 2018-07-11 2021-09-23 Duke University Use of sustained-release 5-hydroxytryptophan in treating gastrointestinal disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4820715A (en) * 1984-06-28 1989-04-11 Bristol-Myers Company Anti-emetic quinuclidinyl benzamides
NZ225152A (en) * 1987-07-17 1990-04-26 Janssen Pharmaceutica Nv Heterocyclically substituted piperidinyl benzamides as pharmaceuticals
US4975439A (en) * 1987-09-25 1990-12-04 Janssen Pharmaceutical N.V. Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
IL89848A (en) * 1988-04-07 1997-08-14 Sepracor Chiral ester derivatives
TW243449B (no) * 1991-02-15 1995-03-21 Hokuriku Pharmaceutical
TW294595B (no) * 1992-11-20 1997-01-01 Janssen Pharmaceutica Nv
FR2717174B1 (fr) * 1994-03-14 1996-05-31 Sanofi Sa Utilisation de pipéridinoéthyl esters de l'acide 4-amino-5-chloro-2-méthoxybenzoïque comme 5-HT4 agonistes.
US5712293A (en) * 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
US6147093A (en) * 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
US5739151A (en) 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride

Also Published As

Publication number Publication date
AU757077B2 (en) 2003-01-30
EA002362B1 (ru) 2002-04-25
HRP20000004A2 (en) 2000-12-31
ID24228A (id) 2000-07-13
DE69818678D1 (de) 2003-11-06
NO20000093D0 (no) 2000-01-07
ES2209190T3 (es) 2004-06-16
IL133225A0 (en) 2001-03-19
NO315183B1 (no) 2003-07-28
BG64824B1 (bg) 2006-05-31
CN1196681C (zh) 2005-04-13
AU8857598A (en) 1999-02-08
WO1999002496A1 (en) 1999-01-21
CN1262675A (zh) 2000-08-09
SK182999A3 (en) 2000-08-14
CZ296212B6 (cs) 2006-02-15
PT1000029E (pt) 2004-02-27
JP3529102B2 (ja) 2004-05-24
US20030060485A1 (en) 2003-03-27
IL133225A (en) 2005-12-18
EE04491B1 (et) 2005-06-15
TW553934B (en) 2003-09-21
BG103934A (en) 2000-11-30
EP1000029B1 (en) 2003-10-01
HK1025092A1 (en) 2000-11-03
MY129130A (en) 2007-03-30
EA200000057A1 (ru) 2000-08-28
JP2000515560A (ja) 2000-11-21
EP1000029A1 (en) 2000-05-17
EE200000014A (et) 2000-10-16
PL190296B1 (pl) 2005-11-30
US20040176414A1 (en) 2004-09-09
BR9811676A (pt) 2000-09-19
ATE251139T1 (de) 2003-10-15
KR100358374B1 (ko) 2002-10-25
DE69818678T2 (de) 2004-07-15
DK1000029T3 (da) 2004-02-23
KR20010014027A (ko) 2001-02-26
TR200000020T2 (tr) 2000-09-21
PL337648A1 (en) 2000-08-28
HUP0003078A2 (hu) 2001-01-29
HUP0003078A3 (en) 2002-02-28
CZ461799A3 (cs) 2000-05-17
CO4940432A1 (es) 2000-07-24
SK284941B6 (sk) 2006-02-02
NZ502207A (en) 2001-08-31
CA2292480A1 (en) 1999-01-21

Similar Documents

Publication Publication Date Title
NO20000093L (no) (+)-Norcisaprid nyttig for 5-HT3 og 5-HT4-medierte forstyrrelser
MX9707980A (es) Derivados de 4-aminoquinazolina, composiciones que los contienen, y uso de los mismos.
RO116900B1 (ro) Derivaţi de dihidrobenzopiran, procedeu pentru prepararea acestora, intermediar pentru realizarea procedeului, compoziţie farmaceutică şi metodă de tratament
IS1904B (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
BR0007643A (pt) Processo para obter ésteres de (nitroximetil) fenila de derivados de aspirina, e, (hidroximetil) feniléter de derivados de aspirina
ES2173422T3 (es) Disociacion de treo-metilfenidato.
SI1274685T1 (sl) Derivat piridin-1-oksida in postopek njegove transformacije v farmacevtsko ucinkovite sestavine
GR930100090A (el) Μέ?οδος για την παραγωγή αλάτων κλαβουλανικού οξέος.
CA2296560A1 (en) Amino acid derivatives useful to treat stroke
HUP0103712A2 (hu) Paroxetin sók, eljárás az előállításukra és gyógyászati alkalmazásuk
PT92234A (pt) Processo para a preparacao de 1,2,3,4-tetraidro-1,9-acridinodiaminas
TW338035B (en) Process for the production of enantiomerically-pure-azetidine-2-carboxylic acid
ZA976854B (en) Treatment of psychotic disorders.
PL338147A1 (en) Derivatives of polyhydroxylbutylpyrazine, method of obtaining and drugs containing them
MX9704704A (es) Amidas de acido 4-amino-2-ureido-pirimidin-5-carboxilico, procedimientos para su obtencion, medicamentos que contienen estos compuestos, y su utilizacion.
ES2147499A1 (es) Derivados de acidos carboxilicos, metodo para su elaboracion y agentes terapeuticos que contienen estos compuestos.
MX9604692A (es) Derivados de quinoxalina para el tratamiento de tinnitus.
PL352119A1 (en) Derivatives of aminotetraline for treatment of cardiovascular diseases
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
IL116262A0 (en) Processes for preparing ranitidine
MY124089A (en) Use of cetirizine for preventing the onset of asthma
SE9901340D0 (sv) Novel process
JO2127B1 (en) How to prevent asthma
JO1720B1 (en) Heterocyclic derivatives
SE9901338D0 (sv) Novel process